Free Trial
→ Elon Musk’s One Stock Retirement Plan (From Brownstone Research) (Ad)tc pixel Free PYC Stock Alerts

Physiomics (PYC) Competitors

Physiomics logo
GBX 0.45 -0.02 (-4.63%)
As of 09:58 AM Eastern
Compare

PYC vs. SNG, BVX, TLM, BNR, and NFX

Should you buy Physiomics stock or one of its competitors? Physiomics's main competitors and comparable companies include Synairgen (SNG), BiVictriX Therapeutics (BVX), Talisman Metals (TLM), Burning Rock Biotech (BNR), and Nuformix (NFX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Physiomics compare to Synairgen?

Synairgen (LON:SNG) and Physiomics (LON:PYC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Physiomics has higher revenue and earnings than Synairgen. Physiomics is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SynairgenN/AN/A-£15.86M-£1.66N/A
Physiomics£953.01K2.24-£922.82K-£0.15N/A

In the previous week, Physiomics had 2 more articles in the media than Synairgen. MarketBeat recorded 2 mentions for Physiomics and 0 mentions for Synairgen. Synairgen's average media sentiment score of 0.00 beat Physiomics' score of -0.47 indicating that Synairgen is being referred to more favorably in the media.

Company Overall Sentiment
Synairgen Neutral
Physiomics Neutral

30.7% of Synairgen shares are held by institutional investors. Comparatively, 0.8% of Physiomics shares are held by institutional investors. 3.2% of Synairgen shares are held by company insiders. Comparatively, 20.7% of Physiomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Synairgen has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Synairgen's return on equity of -51.06% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
SynairgenN/A -51.06% -30.58%
Physiomics -50.92%-89.43%-76.38%

Synairgen has a beta of -2.23, suggesting that its share price is 323% less volatile than the broader market. Comparatively, Physiomics has a beta of 1.052, suggesting that its share price is 5% more volatile than the broader market.

Summary

Synairgen and Physiomics tied by winning 6 of the 12 factors compared between the two stocks.

How does Physiomics compare to BiVictriX Therapeutics?

Physiomics (LON:PYC) and BiVictriX Therapeutics (LON:BVX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Physiomics has higher revenue and earnings than BiVictriX Therapeutics. Physiomics is trading at a lower price-to-earnings ratio than BiVictriX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£953.01K2.24-£922.82K-£0.15N/A
BiVictriX TherapeuticsN/AN/A-£2.67M-£0.04N/A

0.8% of Physiomics shares are owned by institutional investors. Comparatively, 30.8% of BiVictriX Therapeutics shares are owned by institutional investors. 20.7% of Physiomics shares are owned by company insiders. Comparatively, 42.6% of BiVictriX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Physiomics had 2 more articles in the media than BiVictriX Therapeutics. MarketBeat recorded 2 mentions for Physiomics and 0 mentions for BiVictriX Therapeutics. BiVictriX Therapeutics' average media sentiment score of 0.00 beat Physiomics' score of -0.47 indicating that BiVictriX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Physiomics Neutral
BiVictriX Therapeutics Neutral

BiVictriX Therapeutics has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Physiomics' return on equity of -89.43% beat BiVictriX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-50.92% -89.43% -76.38%
BiVictriX Therapeutics N/A -103.99%-62.99%

Physiomics has a beta of 1.052, suggesting that its share price is 5% more volatile than the broader market. Comparatively, BiVictriX Therapeutics has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market.

Summary

Physiomics and BiVictriX Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Physiomics compare to Talisman Metals?

Talisman Metals (LON:TLM) and Physiomics (LON:PYC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Physiomics has higher revenue and earnings than Talisman Metals. Physiomics is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talisman MetalsN/AN/A-£1.35M£12.390.73
Physiomics£953.01K2.24-£922.82K-£0.15N/A

In the previous week, Physiomics had 2 more articles in the media than Talisman Metals. MarketBeat recorded 2 mentions for Physiomics and 0 mentions for Talisman Metals. Talisman Metals' average media sentiment score of 0.00 beat Physiomics' score of -0.47 indicating that Talisman Metals is being referred to more favorably in the media.

Company Overall Sentiment
Talisman Metals Neutral
Physiomics Neutral

Talisman Metals has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Talisman Metals' return on equity of 0.00% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Talisman MetalsN/A N/A 3.70%
Physiomics -50.92%-89.43%-76.38%

1.4% of Talisman Metals shares are held by institutional investors. Comparatively, 0.8% of Physiomics shares are held by institutional investors. 95.2% of Talisman Metals shares are held by insiders. Comparatively, 20.7% of Physiomics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Talisman Metals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Physiomics has a beta of 1.052, indicating that its share price is 5% more volatile than the broader market.

Summary

Talisman Metals beats Physiomics on 8 of the 12 factors compared between the two stocks.

How does Physiomics compare to Burning Rock Biotech?

Physiomics (LON:PYC) and Burning Rock Biotech (LON:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

0.8% of Physiomics shares are owned by institutional investors. 20.7% of Physiomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Burning Rock Biotech has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Burning Rock Biotech's return on equity of 0.00% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-50.92% -89.43% -76.38%
Burning Rock Biotech N/A N/A N/A

Burning Rock Biotech has lower revenue, but higher earnings than Physiomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£953.01K2.24-£922.82K-£0.15N/A
Burning Rock BiotechN/AN/AN/AN/AN/A

In the previous week, Physiomics had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for Physiomics and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 beat Physiomics' score of -0.47 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Physiomics Neutral
Burning Rock Biotech Neutral

Summary

Physiomics and Burning Rock Biotech tied by winning 4 of the 8 factors compared between the two stocks.

How does Physiomics compare to Nuformix?

Physiomics (LON:PYC) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

In the previous week, Physiomics had 2 more articles in the media than Nuformix. MarketBeat recorded 2 mentions for Physiomics and 0 mentions for Nuformix. Nuformix's average media sentiment score of 0.00 beat Physiomics' score of -0.47 indicating that Nuformix is being referred to more favorably in the news media.

Company Overall Sentiment
Physiomics Neutral
Nuformix Neutral

0.8% of Physiomics shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 20.7% of Physiomics shares are held by company insiders. Comparatively, 7.5% of Nuformix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nuformix has lower revenue, but higher earnings than Physiomics. Nuformix is trading at a lower price-to-earnings ratio than Physiomics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£953.01K2.24-£922.82K-£0.15N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Physiomics has a beta of 1.052, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.531, suggesting that its stock price is 53% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Nuformix's return on equity of -83.53% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-50.92% -89.43% -76.38%
Nuformix N/A -83.53%-17.20%

Summary

Nuformix beats Physiomics on 7 of the 12 factors compared between the two stocks.

Get Physiomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYC vs. The Competition

Export
MetricPhysiomicsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£2.05M£3.89B£7.28B£2.81B
Dividend Yield6.20%3.65%2.51%6.26%
P/E Ratio-3.0212.99275.44366.75
Price / Sales2.151,141.69559.8088,865.19
Price / Cash4.21118.5077.1627.85
Price / Book2.1716.8810.667.12
Net Income-£922.82K-£22.65M£3.50B£5.89B
7 Day Performance-9.94%-5.64%-3.65%0.21%
1 Month Performance-15.64%-13.53%-8.06%-0.04%
1 Year Performance10.49%6.87%2.58%22.93%

Physiomics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYC
Physiomics
N/AGBX 0.45
-4.6%		N/A+7.3%£2.05M£953.01KN/A10
SNG
Synairgen
N/AN/AN/AN/A£9.04MN/AN/A34
BVX
BiVictriX Therapeutics
N/AN/AN/AN/A£8.25MN/AN/A17
TLM
Talisman Metals
N/AGBX 9
+5.9%		N/AN/A£5.78MN/A0.735
BNR
Burning Rock Biotech
N/AN/AN/AN/A£3.77MN/AN/A1,390

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:PYC) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...
The Tomorrow Investor | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel